Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients

Yang Zhang,Pengcheng Cai,Lei Li,Liang Shi,Panpan Chang,Tao Liang,Qianqian Yang,Yang Liu,Lin Wang,Lihua Hu
DOI: https://doi.org/10.1016/j.intimp.2016.12.024
IF: 5.714
2017-01-01
International Immunopharmacology
Abstract:T-cell immunoglobulin domain and mucin domain-3(TIM-3) is an activation induced inhibitory molecule involved in immune tolerance and is recently reported to induce T cell exhaustion which is mediated by carcinoembryonic antigen cell adhesion molecule 1(CEACAM1), another well-known molecule expressed on activated T cells and involved in T cell inhibition. To investigate the expression of TIM-3 and CEACAM1 on circulating CD8+ T cells and tumor infiltrating lymphocytes (TILs), 65 diagnosed colorectal cancer (CRC) patients and 38 healthy controls were enrolled in this study and the results showed that TIM-3 and CEACAM1 were both highly expressed on circulating CD8+ T cells in CRC patients and elevated on TILs compared with paraneoplastic T cells. Furthermore, TIM-3+CEACAM1+ CD8+ T cells represented the most dysfunctional population with the least IFN-γ production. In addition, the expressions of TIM-3 and CEACAM1 were correlated with advanced stage and could be independent risk factors for CRC. We for the first time to our knowledge suggested that co-expression of TIM-3 and CEACAM1 can mediate T cell exhaustion and may be potential biomarkers for CRC prediction, highlighting the possibility of being immunotherapy targets.
What problem does this paper attempt to address?